SPC
RETA

Slate Path Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Slate Path Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-120,000
Closed -$24.5M – 33
2019
Q4 		$24.5M Hold
120,000
– – 1.32% 15
2019
Q3 		$9.63M Buy
+120,000
New +$10.2M 0.64% 16

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Slate Path Capital's RETA Position: Q1 2020 in Review

Slate Path Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 120,000 shares — an estimated $24.5M sold.

Slate Path Capital first reported a position in RETA in Q3 2019 and held it in 2 quarters. The position peaked at $24.5M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

  • Slate Path Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
  • Slate Path Capital sold 120,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $24.5M.
  • Slate Path Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 2 quarters.
  • Slate Path Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $24.5M in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Slate Path Capital's 13F filing for Q1 2020, filed 15 May 2020.